Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0000920465-21-000008
Filing Date
2021-02-18
Accepted
2021-02-18 16:24:56
Documents
1
Period of Report
2021-02-12

Document Format Files

Seq Description Document Type Size
1 FORM 4 wf-form4_161368346317711.html 4  
1 FORM 4 wf-form4_161368346317711.xml 4 6824
  Complete submission text file 0000920465-21-000008.txt   8207
Mailing Address 4747 EXECUTIVE DRIVE, SUITE 240 SAN DIEGO CA 92121
Business Address 4747 EXECUTIVE DRIVE, SUITE 240 SAN DIEGO CA 92121 858-207-4264
LA JOLLA PHARMACEUTICAL CO (Issuer) CIK: 0000920465 (see all company filings)

EIN.: 330361285 | State of Incorp.: CA | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address 4747 EXECUTIVE DRIVE SUITE 210 SAN DIEGO CA 92121
Business Address
Hearne Michael S (Reporting) CIK: 0001759910 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-36282 | Film No.: 21649866